Involvement of the blood-brain barrier in metabolic regulation

CNS and Neurological Disorders - Drug Targets

Volumn 15, Issue 9, 2016, Pages 1118-1128

  Kastin, Abba J ^a   Pan, Weihong ^b  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b Biopotentials Sleep Center   (United States)

Author keywords

Blood brain barrier; Feeding; Leptin; Obesity; Transport

Indexed keywords

ANIMAL; BLOOD BRAIN BARRIER; EATING; HUMAN; METABOLISM; PHYSIOLOGY;

ANIMALS; BLOOD-BRAIN BARRIER; EATING; HUMANS;

EID: 85022200718     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527315666160920124928     Document Type: Review

References (124)

1. Pan W, Hsuchou H, Tu H, Kastin AJ. Developmental changes of leptin receptors in cerebral microvessels: unexpected relation to leptin transport. Endocrinology 2008; 149: 877-85.
2. Pan W, Kastin AJ. Leptin: a biomarker for sleep disorders? Sleep Med Rev 2014; 18: 283-90.
3. Plotkin SR, Banks WA, Kastin AJ. Comparison of saturable transport and extracellular pathways in the passage of interleukin-1a across the blood-brain barrier. J Neuroimmunol 1996; 67: 41-7.
4. Peruzzo B, Pastor FE, Blazquez JL, et al. A second look at the barriers of the medial basal hypothalamus. Exp Brain Res 2000; 132: 10-26.
5. Blazquez JL, Rodriguez EM. The design of barriers in the hypothalamus allows the median eminence and the arcuate nucleus to enjoy private milieus: the former opens to the portal blood and the latter to the cerebrospinal fluid. Peptides 2010; 31: 757-76.
6. Pan W, Hsuchou H, Jayaram B, et al. Leptin action on nonneuronal cells in the CNS: potential clinical implications. Ann NY Acad Sci 2012; 1264: 64-71.
7. Banks WA, Kastin AJ, Huang W, Jaspan JB, Maness LM. Leptin enters the brain by a saturable system independent of insulin. Peptides 1996; 17: 305-11.
8. Davson H, Segal MB. Special aspects of the blood-brain barrier. In: Davson H, editor. Physiology of the CSF and blood-brain barriers.Boca Raton, Florida: CRC Press; 1996. pp. 303-458.
9. Pan W, Kastin AJ, Daniel J, Yu C, Baryshnikova LM, von Bartheld CS. TNF alpha trafficking in cerebral vascular endothelial cells. J Neuroimmunol 2007; 185: 47-56.
10. Tu H, Pan W, Feucht L, Kastin AJ. Convergent trafficking pattern of leptin after endocytosis mediated by ObRa-ObRd. J Cell Physiol 2007; 212: 215-22.
11. Tu H, Kastin AJ, Hsuchou H, Pan W. Soluble receptor inhibits leptin transport. J Cell Physiol 2008; 214: 301-5.
12. Tu H, Hsuchou H, Kastin AJ, Wu X, Pan W. Unique leptin trafficking by a tailless receptor. FASEB J 2010; 24: 2281-91.
13. Banks WA, Kastin AJ. Measurement of transport of cytokines across the blood-brain barrier. Meth Neurosci 1993; 16: 67-77.
14. Blasberg RG, Fenstermacher JD, Patlak CS. Transport of aaminoisobutyric acid across brain capillary and cellular membranes. J Cereb Blood Flow Metab 1983; 3: 8-32.
15. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983; 3: 1-7.
16. Kastin AJ, Akerstrom V, Pan W. Validity of multiple-time regression analysis in measurement of tritiated and iodinated leptin crossing the blood-brain barrier: meaningful controls. Peptides 2001; 22: 2127-36.
17. Maresh GA, Maness LM, Zadina JE, Kastin AJ. In vitro demonstration of a saturable transport system for leptin across the blood-brain barrier. Life Sci 2001; 69: 67-73.
18. Banks WA, DiPalma CR, Farrell CL. Impaired transport of leptin across the blood-brain barrier in obesity. Peptides 1999; 20: 1341-5.
19. Banks WA, Farrell CL. Impaired transport of leptin across the blood-brain barrier in obesity is acquired and reversible. Am J Physiol 2003; 285: E10-5.
20. Zlokovic BV, Jovanovic S, Miao W, Samara S, Verma S, Farrell CL. Differential regulation of leptin transport by the choroid plexus and blood-brain barrier and high affinity transport systems for entry into hypothalamus and across the blood-cerebrospinal fluid barrier. Endocrinology 2000; 141: 1434-41.
21. Thomas SA, Preston JE, Wilson MR, Farrell CL, Segal MB. Leptin transport at the blood-cerebrospinal fluid barrier using the perfused sheep choroid plexus model. Brain Res 2001; 895: 283-90.
22. Maness LM, Kastin AJ, Farrell CL, Banks WA. Fate of leptin after intracerebroventricular injection into the mouse brain. Endocrinology 1998; 139: 4556-62.
23. Rodriguez EM, Blazquez JL, Pastor FE, et al. Hypothalamic tanycytes: a key component of brain-endocrine interaction. Int Rev Cytol 2005; 247: 89-164.
24. Langdon KD, Clarke J, Corbett D. Long-term exposure to high fat diet is bad for your brain: exacerbation of focal ischemic brain injury. Neuroscience 2011; 182: 82-7.
25. Caro JF, Kolaczynski JW, Nyce MR, et al. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 1996; 348: 159-61.
26. Schwartz MW, Peskind E, Raskind M, Boyko EJ, Porte D, Jr. Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nat Med 1996; 2: 589-93.
27. Van HM, Compton DS, France CF, et al. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest 1997; 99: 385-90.
28. Wu-Peng XS, Chua SC Jr, Okada N, Liu SM, Nicolson M, Leibel RL. Phenotype of the obese Koletsky (f) rat due to Tyr763Stop mutation in the extracellular domain of the leptin receptor (Lepr): evidence for deficient plasma-to-CSF transport of leptin in both the Zucker and Koletsky obese rat. Diabetes 1997; 46: 513-8.
29. Koistinen HA, Karonen SL, Iivanainen M, Koivisto VA. Circulating leptin has saturable transport into intrathecal space in humans. Eur J Clin Invest 1998; 28: 874-97.
30. Maness LM, Banks WA, Kastin AJ. Persistence of blood-to-brain transport of leptin in obese leptin-deficient and leptin receptordeficient mice. Brain Res 2000; 873: 165-7.
31. Banks WA, Clever CM, Farrell CL. Partial saturation and regional variation in the blood-to-brain transport of leptin in normal weight mice. Am J Physiol 2000; 278: E1158-65.
32. Pan W, Kastin AJ. Diurnal variation of leptin entry from blood to brain involving partial saturation of the transport system. Life Sci 2001; 68: 2705-14.
33. Kastin AJ, Akerstrom V. Fasting, but not adrenalectomy, reduces transport of leptin into the brain. Peptides 2000; 21: 679-82.
34. Kastin AJ, Akerstrom V. Glucose and insulin increase the transport of leptin through the blood-brain barrier in normal mice but not in streptozotocin-diabetic mice. Neuroendocrinology 2001; 73: 237-42.
35. Kastin AJ, Pan W. Dynamic regulation of leptin entry into brain by the blood-brain barrier. Regul Peptides 2000; 92: 37-43.
36. Asakawa A, Inui A, Ueno N, Makino S, Fujino MA, Kasuga W. Urocrotin reduces food intake and gastric emptying in lean and ob/ob obese mice. Gastroenterology 1999; 116: 1287-92.
37. Pan W, Hsuchou H, He Y, Kastin AJ. The astroglial leptin receptors and obesity. In: Preedy VR, editor. Modern Insights into Disease-from Molecules to Man: Adipokines. Enfield, NH, USA: Science Publishers; 2011; pp. 185-96.
38. Pan W, Hsuchou H, He Y, et al. Astrocyte Leptin Receptor (ObR) and Leptin Transport in Adult-Onset Obese Mice. Endocrinology 2008; 149: 2798-806.
39. Hsuchou H, He Y, Kastin AJ, et al. Obesity induces functional astrocytic leptin receptors in hypothalamus. Brain 2009; 132: 889-902.
40. Pan W, Hsuchou H, Xu CL, Wu X, Bouret SG, Kastin AJ. Astrocytes modulate distribution and neuronal signaling of leptin in the hypothalamus of obese Avy mice. J Mol Neurosci 2011; 43: 478-84.
41. Jayaram B, Pan W, Wang Y, et al. Astrocytic leptin-receptor knockout mice show partial rescue of leptin resistance in dietinduced obesity. J Appl Physiol 2013; 114: 734-41.
42. Wang Y, Hsuchou H, He Y, Kastin AJ, Pan W. Role of Astrocytes in Leptin Signaling. J Mol Neurosci 2015; 56: 829-39.
43. Wu X, Mishra PK, Hsuchou H, Kastin AJ, Pan W. Upregulation of astrocytic leptin receptor in mice with experimental autoimmune encephalomyelitis. J Mol Neurosci 2013; 49: 446-56.
44. Mishra PK, Hsuchou H, Ouyang S, Kastin AJ, Wu X, Pan W. Loss of astrocytic leptin signaling worsens experimental autoimmune encephalomyelitis. Brain Behav Immun 2013; 34: 98-107.
45. Jayaram B, Khan RS, Kastin AJ, Hsuchou H, Wu X, Pan W. Protective Role of Astrocytic Leptin Signaling Against Excitotoxicity. J Mol Neurosci 2013; 49: 523-30.
46. Hsuchou H, Wang Y, Cornelissen-Guillaume GG, et al. Diminished leptin signaling can alter circadian rhythm of metabolic activity and feeding. J Appl Physiol 2013; 115: 995-1003.
47. He J, Kastin AJ, Wang Y, Pan W. Sleep fragmentation has differential effects on obese and lean mice. J Mol Neurosci 2015; 55: 644-52.
48. Pan W, Kastin AJ. Can sleep apnea cause Alzheimer's disease? Neurosci Biobehav Rev 2014; 47: 656-69.
49. Pan W. From blood to brain through BBB and astrocytic signaling. Peptides 2015; 72: 127.
50. Spina M, Merlo-Pich E, Chan RK, et al. Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science 1996; 273: 1561-4.
51. Vaughan J, Donaldson C, Bittencourt J, et al. Urocortin, A Mammalian Neuropeptide Related to Fish Urotensin-I and to Corticotropin-Releasing Factor. Nature 1995; 378: 287-92.
52. Martins JM, Kastin AJ, Banks WA. Unidirectional specific and modulated brain to blood transport of corticotropin-releasing hormone. Neuroendocrinology 1996; 63: 338-48.
53. Martins JM, Banks WA, Kastin AJ. Acute modulation of active carrier-mediated brain-to-blood transport of corticotropin-releasing hormone. Am J Physiol 1997; 272: E312-9.
54. Kastin AJ, Akerstrom V, Pan W. Activation of urocortin transport into brain by leptin. Peptides 2000; 21: 1811-7.
55. Kastin AJ, Akerstrom V. Pretreatment with glucose increases entry of urocortin into mouse brain. Peptides 2001; 22: 829-34.
56. Tu H, Kastin AJ, Pan W. Corticotropin-releasing hormone receptor (CRHR)1 and CRHR2 are both trafficking and signaling receptors for urocortin. Mol Endocrinol 2007; 21: 700-11.
57. Pan W, Tu H, Hsuchou H, Daniel J, Kastin AJ. Unexpected amplification of leptin-induced Stat3 signaling by urocortin: implications for obesity. J Mol Neurosci 2007; 33: 232-8.
58. Zhang Y, Wu X, He Y, et al. Melanocortin potentiates leptininduced STAT3 signaling via MAPK pathway. J Neurochem 2009; 110: 390-9.
59. Stone KP, Kastin AJ, Pan W. NFêB is an unexpected major mediator of interleukin-15 signaling in cerebral endothelia. J Cell Physiol 2011; 28: 115-24.
60. Ch'ng JL, Christofides ND, Anand P, et al. Distribution of galanin immunoreactivity in the central nervous system and the responses of galanin-containing neuronal pathways to injury. Neuroscience 1985; 16: 343-54.
61. Skofitsch G, Jacobowitz DM. Immunohistochemical mapping of galanin-like neurons in the rat central nervous system. Peptides 1985; 6: 509-46.
62. Ohtaki T, Kumano S, Ishibashi Y, et al. Isolation and cDNA cloning of a novel galanin-like peptide (GALP) from porcine hypothalamus. J Biol Chem 1999; 274: 37041-5.
63. Larm JA, Gundlach AL. Galanin-like peptide (GALP) mRNA expression is restricted to arcuate nucleus of hypothalamus in adult male rat brain. Neuroendocrinology 2000; 72: 67-71.
64. Waters SM, Krause JE. Distribution of galanin-1,-2 and-3 receptor messenger RNAs in central and peripheral rat tissues. Neuroscience 2000; 95: 265-71.
65. Gundlach AL, Ryan PJ. Galanin and GALP. In: Kastin AJ, Ed.; Handbook of biologically active peptides. 2nd ed. Amsterdam: Elsevier; 2013; pp. 766-75.
66. Barson JR, Morganstern I, Leibowitz SF. Galanin. In: Kastin AJ, Ed.; Handbook of biologically active peptides. 2nd ed. Amsterdam: Elsevier; 2013; pp. 1097-103.
67. Kyrkouli SE, Stanley BG, Seirafi RD, Leibowitz SF. Stimulation of feeding by galanin: anatomical localization and behavioral specificity of this peptide's effects in the brain. Peptides 1990; 11: 995-1001.
68. Shioda S, Kageyama H, Takenoya F, Shiba K. Galanin-like peptide: a key player in the homeostatic regulation of feeding and energy metabolism? Int J Obes 2011; 35: 619-28.
69. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006; 43: 173-81.
70. Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 2003; 27: 313-8.
71. Dinulescu DM, Fan W, Boston BA, et al. Mahogany (mg) stimulates feeding and increases basal metabolic rate independent of its suppression of agouti. Proc Natl Acad Sci USA 1998; 95: 12707-12.
72. Nagle DL, McGrail SH, Vitale J, et al. The mahogany protein is a receptor involved in suppression of obesity. Nature 1999; 398: 148-52.
73. Kastin AJ, Akerstrom V. Mahogany (1377-1428) enters brain by a saturable transport system. J Pharmacol Exp Ther 2000; 294: 633-6.
74. Pan W, Kastin AJ, Yu Y, et al. Selective tissue uptake of agoutirelated protein(82-131) and its modulation by fasting. Endocrinology 2005; 146: 5533-9.
75. Kastin AJ, Akerstrom V, Hackler L. Agouti-related protein(83-132) aggregates and crosses the blood-brain barrier slowly. Metabolism 2000; 49: 1444-8.
76. Snodgrass-Belt P, Gilbert JL, Davis FC. Central administration of transforming growth factor-alpha and neuregulin-1 suppress active behaviors and cause weight loss in hamsters. Brain Res 2005; 1038: 171-82.
77. Kastin AJ, Akerstrom V, Hackler L, Zadina JE. Phe(13),Tyr(19)-melanin-concentration hormone and the blood-brain barrier: role of protein binding. J Neurochem 2000; 74: 385-91.
78. Wilson JF. Low permeability of the blood-brain barrier to nanomolar concentrations of immunoreactive alpha-melanotropin. Psychopharmacology 1988; 96: 262-6.
79. Banks WA, Kastin AJ. Peptides and the blood-brain barrier: lipophilicity as a predictor of permeability. Brain Res Bull 1985; 15: 287-92.
80. Forbes S, Bui S, Robinson BR, Hochgeschwender U, Brennan MB. Integrated control of appetite and fat metabolism by the leptinproopiomelanocortin pathway. Proc Natl Acad Sci USA 2001; 98: 4233-7.
81. Kastin AJ, Akerstrom V, Hackler L, Pan W. Adrenomedullin and the blood-brain barrier. Horm Metab Res 2001; 33: 19-25.
82. Fabry Z, Topham DJ, Fee D, et al. TGF-beta 2 decreases migration of lymphocytes in vitro and homing of cells into the central nervous system in vivo. J Immunol 1995; 155: 325-32.
83. Ronaldson PT, Demarco KM, Sanchez-Covarrubias L, Solinsky CM, Davis TP. Transforming growth factor-beta signaling alters substrate permeability and tight junction protein expression at the blood-brain barrier during inflammatory pain. J Cereb Blood Flow Metab 2009; 29: 1084-98.
84. Kastin AJ, Akerstrom V, Pan W. Circulating TGF-b1 does not cross the intact blood-brain barrier. J Mol Neurosci 2003; 21: 43-8.
85. Pan W, Vallance K, Kastin AJ. TGFa and the blood-brain barrier: accumulation in cerebral vasculature. Exp Neurol 1999; 160: 454-9.
86. Pan W, Kastin AJ. Entry of EGF into brain is rapid and saturable. Peptides 1999; 20: 1091-8.
87. Kastin AJ, Akerstrom V, Pan W. Neuregulin-1-beta1 enters brain and spinal cord by receptor-mediated transport. J Neurochem 2004; 88: 965-70.
88. Kastin AJ, Akerstrom V. Nonsaturable entry of neuropeptide Y into brain. Am J Physiol 1999; 276: E479-82.
89. Kastin AJ, Akerstrom V. Entry of CART into brain is rapid but not inhibited by excess CART or leptin. Am J Physiol 1999; 277: E901-4.
90. Kastin AJ, Akerstrom V. Orexin A but not Orexin B rapidly enters brain from blood by simple diffusion. J Pharmacol Exp Ther 1999; 289: 219-23.
91. Chikhale EG, Ng KY, Burton PS, Borchardt RT. Hydrogen bonding potential as a determinant of the in vitro and in situ bloodbrain barrier permeability of peptides. Pharm Res 1994; 11: 412-9.
92. Prasad C, Mori M, Wilber JF, Pierson W, Pegues J, Jayaraman A. Distribution and metabolism of cyclo (His-Pro): a new member of the neuropeptide family. Peptides 1982; 3: 591-8.
93. Banks WA, Kastin AJ, Akerstrom V, Jaspan JB. Radioactively iodinated cyclo(His-Pro) crosses the blood-brain barrier and reverses ethanol-induced narcosis. Am J Physiol 1993; 264: E723-9.
94. Banks WA, Kastin AJ, Maness LM, Huang W, Jaspan JB. Permeability of the blood-brain barrier to amylin. Life Sci 1995; 57: 1993-2001.
95. Banks WA, Kastin AJ. Differential permeability of the blood-brain barrier to two pancreatic peptides: insulin and amylin. Peptides 1998; 19: 883-9.
96. Asakawa A, Inui A, Ueno N, Fujimiya M, Fujino MA, Kasuga M. Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice. Peptides 1999; 20: 1445-8.
97. Baura GD, Foster DM, Porte D Jr, et al. Saturable transport of insulin from plasma into the central nervous system of dogs in vivo: a mechanism for regulated insulin delivery to the brain. J Clin Invest 1993; 92: 1824-30.
98. Banks WA, Jaspan JB, Kastin AJ. Selective, physiological transport of insulin across the blood-brain barrier: novel demonstration by species-specific radioimmunoassays. Peptides 1997; 18: 1257-62.
99. Banks WA, Jaspan JB, Huang W, Kastin AJ. Transport of insulin across the blood-brain barrier: saturability at euglycemic doses of insulin. Peptides 1997; 18: 1423-9.
100. Banks WA, Jaspan JB, Kastin AJ. Effect of diabetes mellitus on the permeability of the blood-brain barrier to insulin. Peptides 1997; 18: 1577-84.
101. Advokat C, Gulati A. Spinal transection reduces both spinal antinociception and CNS concentration of systemically administered morphine in rats. Brain Res 1991; 555: 251-8.
102. Banks WA, Kastin AJ. Opposite direction of transport across the blood-brain barrier for Tyr-MIF-1 and MIF-1: comparison with morphine. Peptides 1994; 15: 23-9.
103. Preston E, Hynie I. Transfer constants for blood-brain barrier permeation of the neuroexcitatory shellfish toxin, domoic acid. Can J Neurol Sci 1991; 18: 39-44.
104. Rosenfeld RG, Pham H, Keller BT, Borchardt RT, Pardridge WM. Demonstration and structural comparison of receptors for insulinlike growth factor-I and-II (IGF-I and-II) in brain and blood-brain barrier. Biochem Biophys Res Commun 1987; 149: 159-66.
105. Pan W, Kastin AJ. Interactions of IGF-1 with the blood-brain barrier in vivo and in situ. Neuroendocrinology 2000; 72: 171-8.
106. Kondo T, Hafezi-Moghadam A, Thomas K, Wagner DD, Kahn CR. Mice lacking insulin or insulin-like growth factor 1 receptors in vascular endothelial cells maintain normal blood-brain barrier. Biochem Biophys Res Commun 2004; 317: 315-20.
107. Kondo T, Vicent D, Suzuma K, et al. Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization. J Clin Invest 2003; 111: 1835-42.
108. Pan W, Yu Y, Yemane R, Cain C, Yu C, Kastin AJ. Permeation of hepatocyte growth factor across the blood-brain barrier. Exp Neurol 2006; 201: 99-104.
109. Kastin AJ, Akerstrom V, Hackler L, Pan W. Different mechanisms influencing permeation of PDGF-AA and PDGF-BB across the blood-brain barrier. J Neurochem 2003; 87: 7-12.
110. Cuevas P, Carceller F, Munoz-Willery I, Gimenez-Gallego G. Intravenous fibroblast growth factor penetrates the blood-brain barrier and protects hippocampal neurons against ischemiareperfusion injury. Surg Neurol 1998; 49: 77-83.
111. Huang B, Krafft PR, Ma Q, et al. Fibroblast growth factors preserve blood-brain barrier integrity through RhoA inhibition after intracerebral hemorrhage in mice. Neurobiol Dis 2012; 46: 204-14.
112. Hsuchou H, Pan W, Kastin AJ. Fibroblast growth factor 19 entry into brain. Fluids Barriers CNS 2013; 10: 32.
113. Pan W, Hsuchou H, Kastin AJ. Nesfatin-1 crosses the blood-brain barrier without saturation. Peptides 2007; 28: 2223-8.
114. Price TO, Samson WK, Niehoff ML, Banks WA. Permeability of the blood-brain barrier to a novel satiety molecule nesfatin-1. Peptides 2007; 28: 2372-81.
115. Inui A, Asakawa A, Bowers CY, et al. Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ. FASEB J 2004; 18: 439-56.
116. Zhang JV, Ren PG, Avsian-Kretchmer O, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005; 310: 996-9.
117. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev 2005; 6: 13-21.
118. Nanayakkara G, Kariharan T, Wang L, Zhong J, Amin R. The cardio-protective signaling and mechanisms of adiponectin. Am J Cardiovasc Dis 2012; 2: 253-66.
119. Pan W, Tu H, Kastin AJ. Differential BBB interactions of three ingestive peptides: Obestatin, ghrelin, and adiponectin. Peptides 2006; 27: 911-6.
120. Banks WA, Tschöp M, Robinson SM, Heiman ML. Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure. J Pharmacol Exp Ther 2002; 302: 822-7.
121. Banks WA, Burney BO, Robinson SM. Effects of triglycerides, obesity, and starvation on ghrelin transport across the blood-brain barrier. Peptides 2008; 29: 2061-5.
122. Lopez NE, Krzyzaniak MJ, Blow C, et al. Ghrelin prevents disruption of the blood-brain barrier after traumatic brain injury. J Neurotrauma 2012; 29: 385-93.
123. Chen YC, Chiang CF, Chen LF, Liao SC, Hsieh WY, Lin WL. Polymersomes conjugated with des-octanoyl ghrelin for the delivery of therapeutic and imaging agents into brain tissues. Biomaterials 2014; 35: 2051-65.
124. Kastin AJ, Pan W. Brain Influx of Endogenous Peptides Affecting Food Intake. In: Sharma HS, Westman J, Eds.; Blood-Spinal Cord and Brain Barriers in Health and Disease. Academic Press, 2004; pp. 57-62.